1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. News
  7. Summary
    4519   JP3519400000


Delayed Japan Exchange  -  05/27 02:00:00 am EDT
3429.00 JPY   -0.46%
05/26Chugai Launches Vabysmo Intravitreal Injection 120 mg/mL for the Treatment of Age-related Macular Degeneration Associated with Subfoveal Choroidal Neovascularization and Diabetic Macular Edema
05/18Judgement On The First Drug Patent Linkage Lawsuit In China Is Issued
04/28Chugai Pharmaceutical Co., Ltd. - Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Pharmaceutical : Actemra Approved for Additional Indication of SARS-CoV-2 Pneumonia in Japan

01/21/2022 | 02:12am EDT

Chugai's Actemra Approved for Additional Indication of

SARS-CoV-2 Pneumonia in Japan

  • The approval is based on the results of several clinical studies in hospitalized patients with COVID-19.

TOKYO, January 21, 2022 --Chugai Pharmaceutical Co., Ltd.(TOKYO: 4519) announced that it obtained regulatory approval from the Ministry of Health, Labour and Welfare for the humanized anti-humanIL-6 receptor monoclonal antibody, "Actemra® Intravenous Infusion 80 mg, 200 mg, and 400 mg" [generic name: tocilizumab (genetical recombination)] for the additional indication of the treatment of SARS-CoV- 2 pneumonia (limited to patients requiring oxygen intervention). The approval came one month after the application for the additional indication on December 13, 2021.

"We are very pleased that Actemra, created by Chugai, has become a new treatment option for SARS-CoV- 2 pneumonia. Clinical studies demonstrated that Actemra reduced the mortality rate in patients with SARS- CoV-2 infection," said Chugai's President and CEO, Dr. Osamu Okuda. "With the rapid spread of SARS- CoV-2 infection caused by Omicron strain, an increase is expected in the number of patients who become severely ill and develop pneumonia requiring oxygen intervention. We hope that Actemra will play a role for the better prognosis of patients with severe, potentially life-threating pneumonia."

This approval is based on the results from clinical studies evaluating Actemra in hospitalized patients, including an investigator-initiated, randomized, open-label, platform overseas study (RECOVERY study), three placebo-controlled, randomized, double-blind, multicenter global phase III studies conducted by Roche (COVACTA study, EMPACTA study, REMDACTA study), and a single-arm, multicenter phase III study in Japan (J-COVACTA study).

Actemra has been approved in the European Union, authorized for emergency use in the United States, and recommended by the World Health Organization for the treatment of COVID-19.

Package insert information *excerpt of revised part

Indications: SARS-CoV-2 pneumonia (limited to patients requiring oxygen intervention)

Dosage and administration: The usual adult dosage is a single intravenous infusion of 8 mg/kg tocilizumab (genetic recombination), in combination with corticosteroids. If symptoms do not improve, an additional single dose of 8 mg/kg tocilizumab (genetic recombination) may be administered 8 hours or more after the end of the initial administration.


Chugai's Actemra/RoActemra Approved by the European Commission to Treat Patients with Severe COVID-19 (Dec 8, 2021) https://www.chugai-pharm.co.jp/english/news/detail/20211208113000_879.html

Roche's Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children (Press release by Roche issued on June 25, 2021) https://www.roche.com/media/releases/med-cor-2021-06-25.htm

Chugai Provides an Update on Phase III COVACTA Study of Actemra in Hospitalized Patients with Severe COVID-19 Associated Pneumonia (July 29, 2020) https://www.chugai-pharm.co.jp/english/news/detail/20200729151500_752.html

Roche's phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia (Press release by Roche issued on September 18, 2020) https://www.roche.com/media/releases/med-cor-2020-09-18.htm

Results of Phase III Clinical Study in Japan for Actemra in COVID-19 Associated Pneumonia (February 9, 2021) https://www.chugai-pharm.co.jp/english/news/detail/20210209150000_803.html

Chugai Provides Update on the Phase III REMDACTA Study of Actemra Plus Remdesivir in Patients with Severe COVID-19 Pneumonia (March 11, 2021) https://www.chugai-pharm.co.jp/english/news/detail/20210311150000_808.html

About Actemra

Actemra is the first therapeutic antibody created in Japan by Chugai. It is designed to block the activity of IL-6, a type of inflammatory cytokine. First launched in June, 2005, the intravenous injection is approved for six indications in Japan: Castlemanʼs disease, rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, cytokine release syndrome induced by tumor-specific T cell infusion therapy, and adult Still's disease. In addition, Actemra subcutaneous injection is approved for three indications in Japan: rheumatoid arthritis, Takayasu arteritis, giant cell arteritis. Actemra has obtained regulatory approval in more than 110 countries worldwide.

Trademarks used or mentioned in this release are protected by laws.


2 / 2


Chugai Pharmaceutical Co. Ltd. published this content on 21 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 January 2022 07:11:01 UTC.

© Publicnow 2022
05/26Chugai Launches Vabysmo Intravitreal Injection 120 mg/mL for the Treatment of Age-relat..
05/18Judgement On The First Drug Patent Linkage Lawsuit In China Is Issued
04/28Chugai Pharmaceutical Co., Ltd. - Notice of Completion of Disposal of Treasury Shares a..
04/27CHUGAI PHARMACEUTICAL : Notice of Completion of Disposal of Treasury Shares as Restricted ..
04/26CHUGAI PHARMACEUTICAL : Script (including Q&A)
04/26Chugai Pharmaceutical Co., Ltd. - Organizational and Personnel Changes
04/26Nikkei 225 Up 0.4% on Wall Street Cues, Softer Interest Rates, Oil Outlook
04/26Chugai Pharmaceutical Logs 178% Surge in Q1 Net Income on Higher Sales
04/25CHUGAI PHARMACEUTICAL : 1Q Results (Jan-Mar 2022)
04/25Chugai Pharmaceutical Co., Ltd. - F. Hoffmann-La Roche Announces First Quarter Sales 20..
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD
More recommendations
Sales 2022 1 187 B 9 320 M 9 320 M
Net income 2022 343 B 2 690 M 2 690 M
Net cash 2022 604 B 4 742 M 4 742 M
P/E ratio 2022 16,5x
Yield 2022 2,26%
Capitalization 5 665 B 44 487 M 44 487 M
EV / Sales 2022 4,26x
EV / Sales 2023 4,74x
Nbr of Employees 7 664
Free-Float 37,8%
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 3 445,00 JPY
Average target price 4 677,69 JPY
Spread / Average Target 35,8%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.90%472 231
PFIZER, INC.-8.57%302 932
ROCHE HOLDING AG-12.16%282 336
ABBVIE INC.11.20%266 074